HUE058912T2 - Liposzóma készítmények - Google Patents

Liposzóma készítmények

Info

Publication number
HUE058912T2
HUE058912T2 HUE13830622A HUE13830622A HUE058912T2 HU E058912 T2 HUE058912 T2 HU E058912T2 HU E13830622 A HUE13830622 A HU E13830622A HU E13830622 A HUE13830622 A HU E13830622A HU E058912 T2 HUE058912 T2 HU E058912T2
Authority
HU
Hungary
Prior art keywords
liposome formulations
liposome
formulations
Prior art date
Application number
HUE13830622A
Other languages
English (en)
Inventor
Arturo Santos
Phillip Frost
Original Assignee
Opko Pharmaceuticals Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50150466&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUE058912(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Opko Pharmaceuticals Llc filed Critical Opko Pharmaceuticals Llc
Publication of HUE058912T2 publication Critical patent/HUE058912T2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Otolaryngology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
HUE13830622A 2012-08-21 2013-08-15 Liposzóma készítmények HUE058912T2 (hu)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261691455P 2012-08-21 2012-08-21
US201361791693P 2013-03-15 2013-03-15
US201361862300P 2013-08-05 2013-08-05

Publications (1)

Publication Number Publication Date
HUE058912T2 true HUE058912T2 (hu) 2022-09-28

Family

ID=50150466

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE13830622A HUE058912T2 (hu) 2012-08-21 2013-08-15 Liposzóma készítmények

Country Status (16)

Country Link
US (2) US10548841B2 (hu)
EP (1) EP2887958B1 (hu)
JP (3) JP6336448B2 (hu)
KR (2) KR102177437B1 (hu)
CN (1) CN104582728A (hu)
AR (1) AR092372A1 (hu)
BR (1) BR112015003658B1 (hu)
CA (2) CA3098856C (hu)
CL (1) CL2015000418A1 (hu)
ES (1) ES2881671T3 (hu)
HU (1) HUE058912T2 (hu)
MX (2) MX363822B (hu)
PL (1) PL2887958T3 (hu)
RU (1) RU2680096C2 (hu)
TW (2) TWI608848B (hu)
WO (1) WO2014031429A2 (hu)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105377890A (zh) * 2013-07-11 2016-03-02 诺华股份有限公司 Vegf拮抗剂治疗早产儿视网膜病变的用途
EP3082784A1 (en) * 2013-12-19 2016-10-26 F.Hoffmann-La Roche Ag Cetp modulator for use in the treatment of eye disease
US20170056469A1 (en) * 2014-05-02 2017-03-02 Mayo Foundation For Medical Education And Research Individualized treatment of eye disease
KR101778004B1 (ko) 2015-06-22 2017-09-15 (주) 에빅스젠 이마티닙을 유효성분으로 포함하는 안구 건조 질환 예방 및 치료용 약학 조성물
TW201720446A (zh) * 2015-11-13 2017-06-16 Ｏｈｒ製藥公司 非典型脈絡膜新生血管（ｃｎｖ）之大小做為以角鯊胺治療之預測子
CN111699004A (zh) * 2018-02-06 2020-09-22 豪夫迈·罗氏有限公司 眼科疾病的治疗
CN113286579A (zh) * 2018-08-23 2021-08-20 埃里克·F·伯恩斯坦 应用抗vegf化合物和使用这类化合物治疗皮肤病的系统、装置和方法
CN109180798B (zh) * 2018-09-04 2020-10-27 武汉原生药谷生物医药科技有限公司 一种增强型治疗性抗体及其应用
US20200323882A1 (en) * 2019-03-15 2020-10-15 University Of Rhode Island Board Of Trustees Phlip®-mediated targeting of corticosteroids to diseased tissue
EP3968949A1 (en) 2019-05-16 2022-03-23 OPKO Pharmaceuticals, LLC Triamcinolone acetonide-loaded liposomes topical ophthalmic formulations for prevention of macular thickening and its associated visual outcomes after lens surgery
CN113546172A (zh) * 2020-04-24 2021-10-26 山东大学齐鲁医院 Vegf抑制剂在制备治疗缺氧相关疾病药物中的应用
US20230241080A1 (en) * 2020-06-15 2023-08-03 Arturo Santos Triamcinolone acetonide-loaded liposomes topical ophthalmic formulations as primary therapy for macular edema secondary to branch retinal vein occlusion
CN116585304B (zh) * 2023-04-25 2024-04-05 四川大学华西医院 一种急性肝损伤保护药物及其制备方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6565861B1 (en) * 2000-02-11 2003-05-20 Isis Innovation Limited Artificial tear formulation
US6610322B1 (en) * 2000-12-20 2003-08-26 Brian Charles Keller Self forming, thermodynamically stable liposomes and their applications
US7785578B2 (en) * 2002-10-11 2010-08-31 Aciont, Inc. Non-invasive ocular drug delivery
US20060165744A1 (en) 2003-05-22 2006-07-27 Neopharm, Inc Combination liposomal formulations
WO2007076274A2 (en) 2005-12-22 2007-07-05 Bausch & Lomb Incorporated Artificial tear solution containing poly (ethylene glycol) peg lipids
EP1965762A1 (en) 2005-12-23 2008-09-10 Alcon, Inc. Pharmaceutical formulation for delivery of receptor tyrosine kinase inhibiting (rtki) compounds to the eye
AU2007323925A1 (en) * 2006-11-10 2008-05-29 Genentech, Inc. Method for treating age-related macular degeneration
MY180595A (en) 2006-12-07 2020-12-03 Genentech Inc Phosphoinositide 3-kinase inhibitor compounds and methods of use
US8216571B2 (en) * 2007-10-22 2012-07-10 Schering Corporation Fully human anti-VEGF antibodies and methods of using
US8887944B2 (en) * 2007-12-11 2014-11-18 Tokitae Llc Temperature-stabilized storage systems configured for storage and stabilization of modular units
EP2361306A1 (en) * 2008-12-04 2011-08-31 OPKO Ophthalmics, LLC Compositions and methods for selective inhibition of pro-angiogenic vegf isoforms
WO2010141068A1 (en) * 2009-06-02 2010-12-09 Wu Nian Opthalmic compositions of cyclosporin
CN102665685A (zh) * 2009-06-02 2012-09-12 念·吴 纯的peg-脂质缀合物
US8956600B2 (en) * 2009-08-10 2015-02-17 Taiwan Liposome Co. Ltd. Ophthalmic drug delivery system containing phospholipid and cholesterol
RU2595718C2 (ru) * 2009-09-09 2016-08-27 Селджен Авиломикс Рисерч,Инк. Ингибиторы pi3-киназы и их применение

Also Published As

Publication number Publication date
JP2018150329A (ja) 2018-09-27
AR092372A1 (es) 2015-04-15
BR112015003658A2 (pt) 2017-07-04
KR20150042215A (ko) 2015-04-20
MX2019001021A (es) 2021-11-16
US20200163877A1 (en) 2020-05-28
PL2887958T3 (pl) 2021-11-22
MX2015002233A (es) 2015-07-06
EP2887958A4 (en) 2016-01-20
CN104582728A (zh) 2015-04-29
US20150224055A1 (en) 2015-08-13
CA3098856C (en) 2023-10-17
MX363822B (es) 2019-04-04
KR20200023507A (ko) 2020-03-04
JP6680827B2 (ja) 2020-04-15
KR102177437B1 (ko) 2020-11-12
CA2879597A1 (en) 2014-02-27
US11712419B2 (en) 2023-08-01
TWI608848B (zh) 2017-12-21
JP2015526467A (ja) 2015-09-10
TW201642838A (zh) 2016-12-16
CL2015000418A1 (es) 2015-07-10
BR112015003658B1 (pt) 2022-09-27
EP2887958A2 (en) 2015-07-01
EP2887958B1 (en) 2021-05-19
JP6336448B2 (ja) 2018-06-06
WO2014031429A2 (en) 2014-02-27
CA2879597C (en) 2021-01-12
ES2881671T3 (es) 2021-11-30
TWI683675B (zh) 2020-02-01
JP7098674B2 (ja) 2022-07-11
US10548841B2 (en) 2020-02-04
WO2014031429A3 (en) 2014-04-24
JP2020111589A (ja) 2020-07-27
RU2680096C2 (ru) 2019-02-15
KR102083700B1 (ko) 2020-03-02
TW201412346A (zh) 2014-04-01
CA3098856A1 (en) 2014-02-27
RU2015107317A (ru) 2016-10-10

Similar Documents

Publication Publication Date Title
HK1255929A1 (zh) 前體脂質體睾酮製劑
AP2014007818A0 (en) Cosmetic
EP2701734A4 (en) LIPOSOMAL FORMULATIONS
EP2887958A4 (en) liposome
SI2877155T1 (sl) Opioidne formulacije
HK1202445A1 (en) New formulation
SG11201504134SA (en) External preparation
EP2821058A4 (en) COSMETIC
EP2861218A4 (en) LIPOSOME FORMULATIONS
IL289157A (en) Opioid compounds
PL2908835T3 (pl) Stabilne formulacje
EP2926804A4 (en) COSMETIC PREPARATION
PL2908859T3 (pl) Formulacje arypiprazolu
GB201110278D0 (en) Formulations
GB201206178D0 (en) Formulations
GB201210088D0 (en) Odontalgic preparation
GB201211247D0 (en) Improved formulation
GB201111578D0 (en) Pharmeutical formulations
GB201111013D0 (en) Formulations
GB201107626D0 (en) Formulations
GB201107627D0 (en) Formulations
GB201105410D0 (en) Formulations
GB201105360D0 (en) Formulations
GB201104049D0 (en) Formulations
GB201104048D0 (en) Formulations